Cite
GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models
MLA
Ciaran M. Regan, et al. “GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer’s Disease Brain and Improves Cognitive Performance in Preclinical Models.” The Journal of Pharmacology and Experimental Therapeutics, vol. 321, no. 3, Mar. 2007. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f2455dc58b48aabeec4028425d545f9f&authtype=sso&custid=ns315887.
APA
Ciaran M. Regan, Sandrine Ociepka, Rebecca K. Davis, Kim Brackenborough, Jane E. Cluderay, Alison M. Ray, Jeffrey Wald, Andrew D. Medhurst, M. Isabel Gonzalez, Michael A. Briggs, David Matthew Wilson, Jason Witherington, Isabel J. M. Beresford, Andrew G. Foley, Laurent Lacroix, Tania O. Stean, Joanne Schogger, Robert P. Davis, Andrew R. Calver, … Jackie Cilia. (2007). GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. The Journal of Pharmacology and Experimental Therapeutics, 321(3).
Chicago
Ciaran M. Regan, Sandrine Ociepka, Rebecca K. Davis, Kim Brackenborough, Jane E. Cluderay, Alison M. Ray, Jeffrey Wald, et al. 2007. “GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer’s Disease Brain and Improves Cognitive Performance in Preclinical Models.” The Journal of Pharmacology and Experimental Therapeutics 321 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f2455dc58b48aabeec4028425d545f9f&authtype=sso&custid=ns315887.